Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: Provided are novel antibody-pyrrolodiazepine derivatives and novel antibody-pyrrolodiazepine derivative conjugates, as well as methods of using the same, and a novel CLDN6 and/or CLDN9 antibody. The disclosed compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics, and include substituted benzo[e]pyrrolo[1,2-?][1,4]diazepine.

Abstract: Provided are novel antibody-pyrrolodiazepine derivative and novel antibody-pyrrolodiazepine derivative conjugates, as well as methods of using the same, and a novel CLDN6 and/or CLDN9 antibody. The disclosed compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics, and include substituted benzo[e]pyrrolo[1,2-?][1,4]diazepine.

Abstract: An image forming apparatus includes a transfer body that rotates and transfers a transferred image to a target transfer body at a transfer position, plural image holding members that rotate together with the transfer body at different positions along a rotation direction of the transfer body while outer peripheral surfaces of the image holding members come into contact with the transfer body, the image holding members on which a charge erasing operation is sequentially performed after images held on the outer peripheral surfaces sequentially transferred to the transfer body, and in which the charge erasing operation on all the image holding members has been ended, and then rotations of all the image holding members are stopped, a first charge erasing unit that erases charges of an outer peripheral surface of at least one image holding member other than a most downstream image holding member disposed on a most downstream side of the rotation direction with respect to the transfer position, among the plural ima

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: An image forming apparatus includes a transfer body that rotates and transfers a transferred image to a target transfer body at a transfer position, plural image holding members that rotate together with the transfer body at different positions along a rotation direction of the transfer body while outer peripheral surfaces of the image holding members come into contact with the transfer body, the image holding members on which a charge erasing operation is sequentially performed after images held on the outer peripheral surfaces sequentially transferred to the transfer body, and in which the charge erasing operation on all the image holding members has been ended, and then rotations of all the image holding members are stopped, a first charge erasing unit that erases charges of an outer peripheral surface of at least one image holding member other than a most downstream image holding member disposed on a most downstream side of the rotation direction with respect to the transfer position, among the plural ima

Abstract: A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: A bearing component for rotatably receiving a rotating shaft on an end of a rotating unit includes a component body, an inner protrusion, and one or more outer protrusions. The component body has a recess into which the rotating shaft is rotatably inserted. The inner protrusion protrudes from a wall portion of the recess facing an end surface of the rotating shaft. The inner protrusion receives an axial load by the rotating shaft. The outer protrusions protrude from an outer surface of the component body opposite to the recess. The one or more outer protrusions are in contact with a holding unit. A contact portion between the outer protrusions and the holding unit is offset from a contact portion position between the inner protrusion and the end surface. The contact portion between at least one of the outer protrusions and the holding unit has a non-planar shape.

Abstract: A bearing component for rotatably receiving a rotating shaft on an end of a rotating unit includes a component body, an inner protrusion, and one or more outer protrusions. The component body has a recess into which the rotating shaft is rotatably inserted. The inner protrusion protrudes from a wall portion of the recess facing an end surface of the rotating shaft. The inner protrusion receives an axial load by the rotating shaft. The outer protrusions protrude from an outer surface of the component body opposite to the recess. The one or more outer protrusions are in contact with a holding unit. A contact portion between the outer protrusions and the holding unit is offset from a contact portion position between the inner protrusion and the end surface. The contact portion between at least one of the outer protrusions and the holding unit has a non-planar shape.

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: An image forming apparatus includes a photoreceptor, a charging unit, an exposure unit, a developing unit, a transfer unit, a detector, and a controller. The charging unit charges the photoreceptor. The exposure unit exposes the photoreceptor charged by the charging unit to light and forms an electrostatic latent image on the photoreceptor. The developing unit develops the electrostatic latent image that has been exposed by the exposure unit and formed on the photoreceptor. The transfer unit transfers an image obtained by development by the developing unit to a transfer object. The detector detects strip developer, which is a strip-shaped developer image formed on the transfer object.

Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.